STOCK TITAN

Spectral AI, Inc. - MDAI STOCK NEWS

Welcome to our dedicated page for Spectral AI news (Ticker: MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.

Spectral AI, Inc. (Nasdaq: MDAI) is an artificial intelligence company dedicated to advancing medical diagnostics, particularly in wound care. The company's flagship product, the DeepView™ System, is a cutting-edge multispectral imaging (MSI) device designed to assist physicians in making accurate and timely treatment decisions. This innovative technology leverages proprietary algorithms to differentiate between damaged and healthy tissue, producing critical Day One healing assessments within seconds.

Spectral AI's DeepView System has received FDA Breakthrough Device Designation due to its potential to significantly improve patient outcomes. The primary focus of the company lies in the research and development of this system. Notably, a substantial portion of its funding comes from the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.

In recent developments, Spectral AI was honored with the Commitment to Quality Achievement Award by the Texas Manufacturer Assistance Center (TMAC) for their attainment of the UKCA Mark. This accolade underscores the company’s dedication to maintaining the highest standards of quality while working towards the commercialization of DeepView technology.

The company frequently updates its stakeholders through conference calls and presentations, which can be accessed via the investor relations section of its website. This proactive communication strategy ensures transparency and keeps investors well-informed about the company's progress and financial health.

Investor Relations Contacts:

Devin Sullivan, Managing Director at The Equity Group, can be reached at dsullivan@equityny.com.

Conor Rodriguez, Analyst at The Equity Group, can be contacted at crodriguez@equityny.com.

Media Contacts:

David Schull of Russo Partners can be reached at david.schull@russopartnersllc.com or (858) 717-2310.

Rhea-AI Summary
Spectral AI, Inc. appoints Peter M. Carlson as CEO, transitioning Wensheng Fan to Chief Innovation Strategist. The Company announces preliminary 2023 R&D revenue of $18 million and reaffirms $28 million revenue guidance for 2024. Spectral AI highlights first quarter momentum and key milestones in commercialization of AI-powered wound care technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
management AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announces participation in investor conferences to showcase their AI technology for medical diagnostics in wound care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
conferences AI
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) announces the UKCA authorization for its DeepView AI®-Burn predictive software, allowing for faster burn wound diagnosis. Revenue from UK commercialization in 2024 is expected to contribute to the Company's $28 million revenue guidance. The technology boasts 92% accuracy in distinguishing healthy and damaged tissue, potentially revolutionizing burn wound management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
Rhea-AI Summary
Spectral AI, Inc. appoints Dr. J. Michael DiMaio to its Board of Directors, extending lock-up agreements for major stockholders. Dr. DiMaio brings extensive medical and research expertise to support the company's AI-driven wound imaging technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
management AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024. The company will host investor meetings during the conference, offering an opportunity for virtual or in-person meetings. This event aims to showcase Spectral AI's focus on medical diagnostics for wound care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
conferences AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a Letter to Shareholders detailing the Company's progress towards commercializing its AI-driven DeepView System for wound assessment and treatment. The letter highlights a $149 million contract from BARDA, revenue generation expectations, FDA and UKCA marking for proprietary technology, promising interim results for DFU Clinical Study, and new management appointments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
AI
Rhea-AI Summary
Spectral MD, Inc. announces the submission of an application in the UK for its predictive software DeepView AI®-Burn to be registered as UK Conformity Assessed for burn wound use. This marks a significant step towards commercialization for the company's AI software in the medical diagnostics field, specifically for thermal burn wounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) announces the enrollment of the first patient in the pivotal study to validate DeepView AI® for burn size and healing assessment. The study is expected to be the final clinical trial before seeking FDA marketing authorization in 2025. The company continues to utilize $251 million of non-dilutive government funding since 2019 to validate DeepView for burn indication and other clinical indications like diabetic foot ulcers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) has announced the hiring of Peter M. Carlson as Chief Financial Officer. Carlson brings a strong track record in senior financial executive roles at public companies, including healthcare entities, and will play a crucial role in navigating the financial landscape and strategic opportunities for Spectral AI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.23%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) is an AI company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care. The company announced its participation in the Benchmark 12th Annual Discovery One-on-One Conference in New York City. Spectral AI's DeepView® System has received a significant contract from the U.S. Government and has been validated through multiple clinical studies for assessing burn wounds and diabetic foot ulcers. The company expects to submit applications for FDA, UKCA, and CE mark approval for its DeepView® System in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.96%
Tags
conferences AI

FAQ

What is the current stock price of Spectral AI (MDAI)?

The current stock price of Spectral AI (MDAI) is $1.89 as of December 20, 2024.

What is the market cap of Spectral AI (MDAI)?

The market cap of Spectral AI (MDAI) is approximately 39.7M.

What does Spectral AI, Inc. specialize in?

Spectral AI specializes in AI-based medical diagnostics, particularly focusing on wound care through their DeepView System.

What is the DeepView System?

The DeepView System is a multispectral imaging device that uses AI algorithms to distinguish between damaged and healthy tissue, aiding in quicker and more accurate treatment decisions.

Has the DeepView System received any regulatory recognition?

Yes, the DeepView System has received FDA Breakthrough Device Designation.

Where does Spectral AI get its research funding?

A substantial portion of Spectral AI's funding comes from the Biomedical Advanced Research and Development Authority (BARDA).

What recent award has Spectral AI received?

Spectral AI recently received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center.

How can investors stay updated on Spectral AI's progress?

Investors can stay updated through conference calls and presentations available on the investor relations section of the company's website.

Who are the media contacts for Spectral AI?

David Schull of Russo Partners, reachable at david.schull@russopartnersllc.com or (858) 717-2310, is the media contact.

What is the role of BARDA in Spectral AI's operations?

BARDA provides essential research and development funding for Spectral AI's projects.

What kind of assessments does the DeepView System provide?

The DeepView System provides Day One healing assessments, allowing for accurate and timely treatment decisions.

Who are the investor relations contacts at Spectral AI?

Devin Sullivan, Managing Director, and Conor Rodriguez, Analyst, both at The Equity Group, are the investor relations contacts.

Spectral AI, Inc.

Nasdaq:MDAI

MDAI Rankings

MDAI Stock Data

39.66M
12.12M
42.18%
15.82%
4.31%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
DALLAS